My last post before this was literally entailing COLLABORATION... its called reading between the lines. Then todays news...
https://themarketherald.ca/claritas-formerly-kalytera-therapeutics-inc-to-collaborate-with-salzman-group-and-other-companies-to-accelerate-development-of-r-107-for-treatment-of-vaccine-resistant-covid-19-influenza-and-oth-2021-03-03/?utm_source=stockhouse.com&utm_medium=widget&utm_campaign=stockhouse.com%7Cwebpart_news%7Cquote_tab To expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companiesSalzman Group will share its expertise in working with nitric oxide and nitric oxide-releasing compoundsR-107 can be administered orally, by injection or by use of a nasal sprayR-107 is expected to allow treatment without the need for special delivery equipment or trained respiratory therapistsPhase 1 clinical study of intramuscular R-107 will be conducted at CMAX in AdelaideClaritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical companyClaritas (KLY) is down 15.38 per cent, trading at C$0.55 per share at 1 pm EST
Claritas Pharmaceuticals has entered into a strategic collaboration agreement with Salzman Group, to expedite the development of R-107.
Claritas is in the process of entering into similar collaborative agreements with other companies.
To expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies for the manufacture of R-107, and for the design and completion of clinical studies to demonstrate the safety and efficacy of R-107 in the treatment of COVID-19, influenza, and other viral infections.
Under the agreement, Salzman Group will make available to Claritas its expertise in working with nitric oxide and nitric oxide-releasing compounds.
Salzman Group will also provide a platform of services, including expertise in the manufacture of R-107, design of clinical studies, and consulting services in connection with Claritas’ interactions with regulatory bodies in the USA, Australia, the UK, and the EU.
“Nitric oxide has a well-documented safety profile and has been demonstrated to be effective against a wide variety of viruses,” stated Dr. Andrew Salzman, Chairman of the Salzman Group.
“Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas, and must be administered by inhalation therapy. Our group has worked to design a nitric oxide-releasing compound to overcome these issues.
This multi-year effort was successful, and resulted in the invention of R-107, which can be administered orally as a capsule, or nasally through use of a nasal spray, or by injection.”
Dr. Salzman continued,
“We are delighted to be working with Claritas to develop R-107, not only as a therapy for vaccine-resistant COVID-19 infection but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.”...